ML-7 Hydrochloride: Selective MLCK Inhibitor for Cardiovascular Research

Executive Summary: ML-7 hydrochloride (SKU: A3626, APExBIO) is a selective myosin light chain kinase (MLCK) inhibitor with a Ki of 300 nM, enabling precise modulation of myosin light chain (MLC) phosphorylation in muscle and vascular studies (APExBIO). The compound demonstrates high water solubility (≥8.82 mg/mL with gentle warming), robust performance in ischemia/reperfusion (I/R) cardiac models, and regulatory effects on tight junction proteins in atherosclerosis research (Wei et al., 2019). ML-7 hydrochloride provides reproducible inhibition of MLCK-mediated pathways, supporting both in vitro and in vivo cardiovascular investigations. Short-term storage at -20°C preserves solution integrity, and purity is typically ≥98% for research-only applications.

Biological Rationale

Myosin light chain kinase (MLCK) is a critical enzyme that phosphorylates myosin light chain (MLC), regulating actin-myosin interactions essential for muscle contraction and cellular motility. Dysregulation of MLCK activity contributes to pathological processes, including cardiovascular disease, endothelial dysfunction, and atherosclerosis (Blebbistatin.com). Selective inhibition of the MLCK pathway permits targeted investigation of cytoskeletal dynamics, contractility, and barrier function in both cardiac and vascular tissues. ML-7 hydrochloride is a tool of choice for researchers aiming to dissect MLCK-dependent mechanisms in disease modeling and translational studies.

Mechanism of Action of ML-7 hydrochloride

ML-7 hydrochloride (1-((5-iodonaphthalen-1-yl)sulfonyl)-1,4-diazepane hydrochloride) competitively inhibits MLCK with a Ki of 300 nM, blocking ATP binding to the kinase catalytic domain. This inhibition prevents MLCK-mediated phosphorylation of MLC, directly suppressing contractile force generation in smooth muscle and cardiac myocytes (APExBIO). By modulating MLC phosphorylation, ML-7 hydrochloride affects actin-myosin crossbridge cycling, cell shape, and paracellular permeability. In endothelial models, ML-7 reduces phosphorylation of tight junction proteins such as ZO1 and occludin, reinforcing barrier function. The compound’s mechanism is specific for MLCK and does not significantly inhibit unrelated kinases at effective concentrations.

Evidence & Benchmarks

• ML-7 hydrochloride inhibits MLCK activity with a Ki of 300 nM under standard assay conditions (pH 7.4, 25°C) (APExBIO).
• In neonatal rat cardiomyocytes, ML-7 blocks sarcomeric organization restoration induced by recombinant human neuregulin-1 (rhNRG-1) (10 μM, 24 h) (Wei et al., 2019).
• Pre-ischemia and reperfusion administration of ML-7 (1 mg/kg, i.v.) in rat models improves heart contractility and decreases oxidative stress markers (phosphatase-inhibitor.com).
• ML-7 ameliorates vascular endothelial dysfunction and atherosclerosis in rabbit models via downregulation of MLCK and reduced MLC phosphorylation (5 mg/kg/d, 4 weeks) (Blebbistatin.com).
• The compound is soluble in DMSO (≥15.95 mg/mL) and water (≥8.82 mg/mL with gentle warming), but insoluble in ethanol (APExBIO).
• Solutions retain >95% activity when stored at -20°C for up to 2 weeks (paricalcitolchem.com).

Applications, Limits & Misconceptions

ML-7 hydrochloride is employed in diverse experimental setups:

• Cardiovascular disease modeling, especially ischemia/reperfusion (I/R) injury research.
• Vascular endothelial dysfunction and atherosclerosis studies, leveraging tight junction protein regulation.
• Cell motility and cytoskeletal reorganization assays in both primary and immortalized cell lines.
• Validation of MLCK-specific signaling via dose-dependent inhibition of MLC phosphorylation.

This article extends previous insights by providing updated protocol details and linking ML-7 hydrochloride to advanced translational models, in contrast to earlier overviews focused on basic cytoskeletal regulation.

Common Pitfalls or Misconceptions

• ML-7 hydrochloride is not a pan-kinase inhibitor; its selectivity is high for MLCK, but not absolute at supra-pharmacological concentrations.
• It does not inhibit caveola-mediated endocytosis; its primary effects are on MLCK-dependent pathways (Wei et al., 2019).
• The compound is intended for research use only; it is not suitable for clinical or diagnostic applications.
• Solubility in ethanol is negligible; DMSO or water (with warming/ultrasonication) should be used for solution preparation.
• Long-term solution storage (>2 weeks) leads to reduced potency; prepare fresh aliquots as needed.

Workflow Integration & Parameters

ML-7 hydrochloride is supplied by APExBIO as a dry powder (SKU: A3626) with ≥98% purity. Reconstitute with DMSO (≥15.95 mg/mL) or water (≥8.82 mg/mL, gentle warming, ultrasonication recommended). Store stock solutions at -20°C, and avoid repeated freeze-thaw cycles. For in vitro assays, typical working concentrations range from 1–20 μM, depending on cell type and endpoint (paricalcitolchem.com). For in vivo models, dosages of 1–5 mg/kg body weight have been validated in rodent and rabbit studies. Always verify MLCK inhibition via downstream markers, such as MLC phosphorylation status, and include appropriate controls.

Researchers seeking advanced protocol guidance for ML-7 hydrochloride in translational settings can consult this strategic review, which maps the compound’s use in complex disease models. This article updates those findings with new solubility and stability data.

Conclusion & Outlook

ML-7 hydrochloride remains a cornerstone tool for cardiovascular, cytoskeletal, and vascular research. Its high selectivity and defined mechanism enable reproducible, targeted inhibition of the MLCK pathway. Continuous product validation and detailed benchmarking, as described here, reinforce its value in both standard and advanced experimental designs. For product specifications and ordering, refer to the APExBIO ML-7 hydrochloride page. As new MLCK-related disease models emerge, ML-7 will continue to support mechanistic and translational exploration.